CIK 0001661998 · Non-accelerated filer<br>Smaller reporting company
Q32 Bio Inc.
Sign in to watch- Ticker
- QTTB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473468154
- Phone
- 781-999-0232
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Former names
- Q32 Bio Inc., Homology Medicines, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $320,396
- in 6 filings
Net −$320,396. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-02 | Morrison Jodie Pope CEO | Sale | −22,506 | $3.46 | $78K | 99,000 |
| 2025-12-02 | Kalowski Lee CFO and President | Sale | −9,072 | $3.46 | $31K | 39,938 |
| 2025-10-23 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-10-23 | Iwicki Mark T Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-10-23 | Manke Isaac Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-10-23 | Xu Diyong Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-10-23 | Thistle Mary Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-10-23 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-10-23 | TZIANABOS ARTHUR Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-10-23 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +53,521 | 53,521 | ||
| 2025-08-26 | Morrison Jodie Pope CEO | Sale | −10,494 | $1.80 | $19K | 121,506 |
| 2025-08-26 | Violette Shelia M. Chief Scientific Officer | Sale | −2,990 | $1.80 | $5K | 58,384 |
| 2025-08-26 | Kalowski Lee CFO and President | Sale | −4,240 | $1.80 | $8K | 49,010 |
| 2025-02-24 | Manke Isaac Director | Returned to the company · Stock Option (Right to Buy) | −12,767 | 0 | ||
| 2025-02-24 | Manke Isaac Director | Grant or award · Stock Option (Right to Buy) | +12,767 | 12,767 | ||
| 2025-02-24 | Manke Isaac Director | Returned to the company · Stock Option (Right to Buy) | −2,627 | 0 | ||
| 2025-02-24 | Manke Isaac Director | Grant or award · Stock Option (Right to Buy) | +2,627 | 2,627 | ||
| 2025-02-24 | Manke Isaac Director | Returned to the company · Stock Option (Right to Buy) | +19,008 | 0 | ||
| 2025-02-24 | Manke Isaac Director | Grant or award · Stock Option (Right to Buy) | +19,008 | 19,008 | ||
| 2025-02-24 | Kalowski Lee CFO and President | Grant or award | +53,250 | 53,250 |
Page 3 of 11 · 207 trades